Www.diabetesclinic.ca 2003 CDA Clinical Practice Guidelines J. Robin Conway M.D. Diabetes Clinic - Smiths Falls, ON Diabetes Office Mgmt www.diabetesclinic.ca.

Slides:



Advertisements
Similar presentations
Insulin Therapy in Type 2 Diabetes: Current and Future Directions
Advertisements

2003 CDA Clinical Practice Guidelines
Organization of Diabetes Care Chapter 6 Maureen Clement, Betty Harvey, Doreen M Rabi, Robert S Roscoe, Diana Sherifali Canadian Diabetes Association 2013.
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Canadian Diabetes Association Clinical Practice Guidelines Hypoglycemia Chapter 14 Dale Clayton, Jean-François Yale, Vincent Woo.
Monitoring diabetes Diabetes Outreach (March 2011)
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association The Essentials Canadian Diabetes Association.
Produced by The Alfred Workforce Development Team on behalf of DHS Public Health - Diabetes Prevention and Management Initiative June 2005 Diabetes Prevention.
Screening for Type 1 and Type 2 Diabetes Chapter 4 Jean-Marie Ekoé, Zubin Punthakee, Thomas Ransom, Ally PH Prebtani, Ron Goldenberg Canadian Diabetes.
Reimbursement Getting Paid for What You Do. Enhancing Reimbursement: What do You Need to Know? Types of health plans and differences Authorization process.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Glucose Tolerance Test Diabetes Mellitus Dr. David Gee FCSN Nutrition Assessment Laboratory.
Diabetes in Pregnancy Screening.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
DR. TARIK Y. ZAMZAMI MD, CABOG, FICS ASSOCIATE PROFESSOR CONSULTANT OB/GYN
BEDTIME INSULIN IN TYPE 2 DIABETES J. Robin Conway M.D. Diabetes Clinic, Smiths Falls,ON
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Combination Therapy in Type 2 Diabetes
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada Canadian Diabetes Association 2003.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
LONG TERM BENEFITS OF ORAL AGENTS
Establishing Preventive Cardiology Programs Nathan Wong Nathan Wong.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Criteria for Diagnosis of DM * Testing must be repeated on separate day. FPG is the preferred test ** Symptoms of DM IFG = Impaired fasting glucose IGT.
DIABETES 1 The Value of Screening: HbA1c as a Diagnostic Tool David Kendall, MD Chief Scientific and Medical Officer American Diabetes.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
IDC Diabetes Update: Recent Research and Impact on Diabetes Management Type 1 DiabetesType 1 Diabetes –Post DCCT findings--improving glycemic control and.
INSULIN THERAPY IN TYPE 1 DIABETES
CDA Clinical Practice Guidelines ORAL AGENTS J. Robin Conway M.D. Diabetes Clinic - Smiths Falls, ON Options for Diabetes
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
CFRD GUIDELINES UPDATE Dr Nigel Paterson, respirologist Tracy Gooyers, nurse case manager Pat Leggatt, dietitian.
Type 2 Diabetes- Treatment Toolbox by: Karen L. Staples, FNP, ACNP Where Do I Start?
What the GP Should Know about Diabetes Mellitus Dr. Muhieddin Omar.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
Estimation of blood glucose in diabetes mellitus.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
GDM-DEFINITION Gestational Diabetes Mellitus (GDM) is defined as ‘carbohydrate intolerance with recognition or onset during pregnancy’, irrespective of.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes National Diabetes Control Programme
IDC 1.1 Global and National Burden of Diabetes Diabetes Mellitus: classification New (WHO) Screening and Diagnostic Criteria –Diabetes, Impaired Glucose.
Glucose Control and Monitoring
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Diabetes mellitus “ Basic approach” Dr Sajith.V.S MBBS,MD (Gen Med )
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association The Essentials Canadian Diabetes Association.
©1999, Medical Age Publishing, Division of Snyder Healthcare Communications Worldwide, Stamford, Connecticut. All rights reserved. Epidemiology and Diagnosis.
Prince Sattam Bin AbdulAziz University College Of Pharmacy Professor Mohammad Abd- elmotaal Mohammad Ruhal Ain, R Ph, PGDPRA, M Pharm Diabetes Mellitus.
1 Diabetes-Where to from here ? Prepared by [Lynne Gilks] [CNC Diabetes Education] [Diabetes Centre, Tamworth] [November 2009]
Source:
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
นพ. เฉลิมศักดิ์ สุวิชัย โรงพยาบาล พะเยา. Management of Type 2 Diabetes Mellitus: A New Paradigm Approach Dr. Chalermsak Suwichai Phayao Hospital.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Measures of Hyperglycemia Random plasma glucose (RPG)—without regard to time of last meal Fasting plasma glucose (FPG)—before breakfast Oral glucose tolerance.
A two stage screening process – the pre-diabetes pathway.
Copyright © 2016, 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc. Chapter 64-Iggy Pg Care of Patients with Diabetes Mellitus.
Screening System for Hypertension and Diabetes at Primary Care Level
CHANGES in ada 2015.
Optimal Blood Glucose Monitoring
Estimation of blood glucose in diabetes mellitus
Care of Patients with Diabetes Mellitus
Diabetes Health Status Report
Screening and Monitoring
Diabetes.
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
Goals & Guidelines A summary of international guidelines for CHD
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

CDA Clinical Practice Guidelines J. Robin Conway M.D. Diabetes Clinic - Smiths Falls, ON Diabetes Office Mgmt Toronto May

Prevalence (millions) North America Europe Southeast Asia Year World Health Organization Canadian Diabetes Association, 1998 website. Worldwide rates of diabetes mellitus: predictions

Frequency of diagnosed and undiagnosed diabetes and IGT, by age (U.S. data - Harris) 2 Million Canadians Have Diabetes Mellitus Harris. Diabetes Care 1993;16:

Am J Cardiol 1999;84:11J-4J. Framingham study: diabetes and CAD mortality at 20-year follow-up Cardiovascular Disease Risk is Increased 2 to 4 Times

What proportion of your office visits involve Diabetics? 1.<10% % % % 5.>50%

The burden of Diabetes 87% of Type 2 Diabetes is managed in Primary Care Diascan Study: 23.5% of patients in our office have diabetes Quebec screening >2 Risk Factors 79% tested 7% Diabetes 13% IGT or IFG 74% No Treatment Advice Strychar I et al. Cdn J Diab 2003(abs) Leiter et al. Diabetes Care 2000

Glucose Monitoring Do you do A1c to follow glycemic control 1= YES 2= NO

Microvascular Complications Do you order urine microalbumen test 1= YES 2= NO

Microvascular Complications Do you use a 10 gm filament for testing sensation in the feet? 1= YES 2= NO

T2DM in Family Practice 84% of patients had A1c in past year Average A1c 7.9% (goal<7%) 88% had BP check 48% had lipid profiles 28% tested for microalbuminuria 15% had foot exams Harris S et al. Cdn Fam Phys 2003

Organization and Delivery of Care Diabetes should be organized using a DHC (Diabetes Healthcare) team approach People with diabetes should be offered initial and ongoing needs-based diabetes education The role of diabetes nurse educators and other DHC team members should be enhanced in cooperation with the physician

Structured care ACLS ATLS Seattle Defibrillator Experience GREACE Study

Structured Care VS Usual Care Αthyros VG et al. Curr Med Res Opin. 2002;18: Patients received atorvastatin 10 mg/d (titrated up to 80 mg/d) to reach the NCEP LDL-C goal Specialist care unit with a strict protocol to achieve NCEP LDL-C target Treatment from a physician of pt’s choice All patients had access to any necessary medications, including statins Included lifestyle modifications (diet and exercise) as well as lipid-lowering medications Structured Care: Usual Care:

Reduction in Relative Risk of Primary Endpoints Αthyros VG et al. Curr Med Res Opin. 2002;18: % Reduction P= P= P= P=0.034 P= P= P=0.021

Type 2 Diabetes Increasing Prevalence Primary Care Based Forms a large part of a practice Needs structured care approach Team Approach Multiple comorbidities Limited Time & Funding

How can we deal with this? Refer all Diabetic Patients? Community Education Programs? Guidelines Based Structured Care? Identify the Diabetics in the practice? Diabetes Day in Office? Get some Diabetes CME? Team Approach in Office? Office Tools?

Diabetes Day in the Office Book Diabetic Patients for one day Get office support staff to follow formula Office staff do Wt, BMI, BP, Glucose, lab Have educational material, consider 1 room Follow Guideline Algorithms Use Tools & Flowsheet Extra Staff? Follow up Appt & Lab

Educational Material Canadian Diabetes Assoc: Pharma Companies; Lilly, Novo, Bayer Web Site list Hospital Diabetes Education Program Community Diabetes Education Program

Screening and Prevention - Type 2 Diabetes Screen all persons >40 years for type 2 diabetes, with a fasting blood glucose (FPG), every 3 years. For people with risk factors, screen earlier and /or more frequently, with either FPG or Oral Glucose Tolerance test (OGTT). If the FPG is 5.7 – 6.9mmol/L and suspicion of diabetes or IGT is high, recommend a 2hPG in a 75-g OGTT.

Every 3 Years in individuals  40 years of age with no other risk factors Earlier and/or more frequently in individuals < 40 years of age with risk factors FPG < 5.7 mmol/L mmol/L plus risk factor(s) for diabetes/IGT mmol/L and not risk factors for diabetes/IGT  7.0 mmol/L 2hPG in 75-g OGTT Classify patients as normal, IFG (isolated), IGT (isolated), IFG & IGT or Diabetes Isolated IFG, Isolated IGT OR IFG & IGTIFG Diabetes Normal Rescreen as clinically indicated Strategies for prevention and rescreen at appropriate intervals Treatment Screening for Type 2 Diabetes, IFG and IGT

Diagnostic Criteria Diagnosis of diabetes FPG  7.0 mmol/L or Casual PG  11.1 mmol/L + symptoms of diabetes or 2hPG in a 75g OGTT  11.1 mmol/L FPG = fasting plasma glucose, no caloric intake for at least 8 hours OGTT = oral glucose tolerance test 2hPG = 2-hour plasma glucose Casual PG = any time of the day, without regard to the interval since the last meal Classic symptoms of diabetes = polyuria, polydipsia and unexplained weight loss A confirmatory laboratory glucose test must be done on another day unless there is unequivocal hyperglycemia and acute metabolic decompensation

Physical Activity and Diabetes For people who have not previously exercised regularly and are at risk of CVD, an ECG stress test should be considered prior to starting an exercise program Testing is particularly important before, during and for many hours after exercise.

Nutrition Therapy People with diabetes should: Receive nutrition counseling by a registered dietitian Receive individualized meal planning Follow Canada’s Guidelines for Healthy Eating People on intensive insulin should also be taught to adjust the insulin for the amount of carbohydrate consumed

Recommended targets for glycemic control* A1C** (%) FPG/preprandial PG (mmol/L) 2-hour postprandial PG (mmol/L) Target for most patients  Normal range (considered for patients in whom it can be achieved safely)  *Treatment goals and strategies must be tailored to the patient, with consideration given to individual risk factors. † Glycemic targets for children  12 years of age and pregnant women differ from these targets. Please refer to “Other Relevant Guidelines” for further details. **An A1C of 7.0% corresponds to a laboratory value of Where possible, Canadian laboratories should standardize their A1C values to DCCT levels (reference range: to 0.060). However, as many laboratories continue to use a different reference range, the target A1C value should be adjusted based on the specific reference range used by the laboratory that performed the test. As a useful guide: an A1C target of 7.0% refers to a threshold that is approximately 15% above the upper limit of normal. A1C = glycosylated hemoglobin DCCT = Diabetes Control and Complications Trial FPG = fasting plasma glucose PG = plasma glucose

Clinical assessment and initiation of nutrition and physical activity Mild to moderate hyperglycemia (A1C <9.0%) Overweight (BMI  25 kg/m 2 ) Non-overweight (BMI  25 kg/m 2 ) Biguanide alone or in combination with 1 of: insulin sensitizer* insulin secretagogue insulin alpha-glucosidase inhibitor 1 or 2 † antihyperglycemic agents from different classes biguanide insulin sensitizer* insulin secretagogue insulin alpha-glucosidase inhibitor Add a drug from a different class or Use insulin alone or in combination with: biguanide insulin secretagogue insulin sensitizer* alpha-glucosidase inhibitor Marked hyperglycemia (A1C  9.0%) 2 antihyperglycemic agents from different classes † biguanide insulin sensitizer* insulin secretagogue insulin alpha-glucosidase inhibitor Basal and/or preprandial insulin Add an oral antihyperglycemic agent from a different class of insulin* Intensify insulin regimen or add biguanide insulin secretagogue** insulin sensitizer* alpha-glucosidase inhibitor If not at target L I F E S T Y L E Timely adjustments to and/or additions of oral antihyperglycemic agents and/or insulin should be made to attain target A1C within 6 to 12 months

Economics Gen AssA003$54.10 Int AssA007$28.50 CounsellingK013$ x/yr Insulin RxK029$ x/yr Type 2 FlowK030$ x/yr GlucoseG002$ 1.97 UrineG009$ 4.20 VenipunctureG489$ 2.27

Economics A003 G002, G009, G489$ G030 G002 G009 G489 x3$ K013 G00s G009 G489 x4$ A007 x4$ TOTAL $517.62

FLOWSHEETS

ABC of Diabetes A 1c <7 B lood Pressure <130/80 C hol/HDL <4, LDL <2.5, Trig <1.5 ACR <2 men, <2.5 women ACE ASA

INVOLVE THE PATIENT

In Conclusion Prevalence of type 2 diabetes is increasing dramatically Majority of patients are diagnosed and treated by the family physician New paradigm: need to be much more aggressive early in the treatment of these patients utilizing dual therapies Hypoglycemia can be managed through proper treatment choices and lifestyle management Glucose is a continuous progressive risk factor for cardiovascular disease

Questions?